DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Icaritin is an investigational drug.
There have been 4 clinical trials for Icaritin. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Osteoporosis, Cardiovascular Diseases, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Chinese Academy of Medical Sciences, Beijing Shenogen Biomedical Co., Ltd, and Qingdao University.
There are three US patents protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for Icaritin
|Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease||National University Hospital, Singapore||Phase 1|
|The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma||307 Hospital of PLA||Phase 2|
|The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma||Chinese Academy of Medical Sciences||Phase 2|
Top disease conditions for Icaritin
Top clinical trial sponsors for Icaritin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Icaritin||Start Trial||Compositions comprising icariside I and anhydroicaritin and methods for making the same||Hauser, Inc. (Boulder, CO)||Start Trial|
|Icaritin||Start Trial||Compounds and methods for treating estrogen receptor-related diseases||Shenogen Pharma Group Ltd. (Beijing, CN)||Start Trial|
|Icaritin||Start Trial||Cosmetic composition containing hydrolysates of icariin||Amorepacific Corporation (Seoul, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Icaritin||World Intellectual Property Organization (WIPO)||0213842||2020-08-15||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|